Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vimizim Panel’s Desire For Quality-Of-Life Data Runs Into Regulatory Reality

Executive Summary

FDA advisory committee overwhelmingly endorses BioMarin’s elosulfase alfa for Morquio A syndrome based on a walking endpoint but says future studies in the rare disease should include QoL assessments, prompting an agency rep to caution that such instruments need to be fully validated for regulatory purposes.


Related Content

Getting With The PRO-gram: Making Patient-Reported Outcomes Work
FDA Takes Long, Skeptical View Of Vimizim’s Six-Minute Walk Endpoint
FDA Awaits Data On Clinical Significance Of Vimizim Neutralizing Antibodies
FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim
Efficacy Endpoint For BioMarin’s Vimizim Faces FDA Panel Scrutiny
Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says
Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes
FDA's Final PRO Guidance Grounds Policy With More Details


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts